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Abstract 
 
DNA microarray expression signatures are expected to provide new insights into 
patho- physiological pathways. Numerous variant statistical methods have been described 
for each step of the signal analysis. We employed five similar statistical tests on the same 
data set at the level of gene selection. Inter-test agreement for the identification of 
biological pathways in BioCarta, KEGG and Reactome was calculated using Cohen’s κ- 
score. The identification of specific biological pathways showed only moderate 
agreement (0.30 < κ < 0.79) between the analysis methods used.  Pathways identified by 
microarrays must be treated cautiously as they vary according to the statistical method 
used.  
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Introduction 
 
DNA microarrays emerged as one of the dominant technologies in biomedical 
research during the past decade. A major promise of the method is thought to lie in the 
potential to identify genes actively involved in patho-physiological pathways1. Discovery 
of such pathways and their genetic regulation may lead to targeted efforts in drug 
discovery.  
It has by now become clear that gene clusters (“signatures”), rather than the 
expression of individual genes, yield higher information contents. The ultimate aim is to 
move from signatures to models, that is, to analyze the data, integrate the information, 
and thus, gain knowledge1.  
The information contained in the expression data is made available through a 
sequence of statistical analyses, which are not yet standardized. Most reports on DNA 
microarray data feature a very unique methodology. Often, the information on the 
methods used is insufficient to allow replication.  
When assessing the usefulness of a technology, much attention must be given to 
the robustness of the knowledge gain, i.e. different observers should come to the same 
conclusion by using this method. 
The present study addresses this point. More precisely, we ask: if one and the 
same set of microarray data is analyzed using different statistical tests at the same 
analytic step, will the same pathways be identified? (The data set and statistical methods 
are described in detail in Appendix A.) This was done by calculating Cohen’s κ - score2, 
which allows to assess whether inter-test agreement is more than a chance product.   
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In addition, we assessed the inter-test mutual agreement at different levels of 
analysis of the data set, namely the biological level (in terms of both gene and pathway 
identification) and the clinical level (case sample clustering). The comparison of these 
test results allows to judge the robustness of the information contents, and the 
independence from the possible introduction of bias through onomastically variant, but de 
facto redundant entries in the protein databases.  
 
 
Results 
 
Each statistical test produced a gene set of 50 genes, according to the conditions 
chosen. There was only partial overlap (Table 1) with not more than three genes common 
to all five tests. The generalized κ-score3 was κ= -28.01.  
At the analytical step of gene selection, Cohen’s κ-score was low (0.15 < κ < 
0.68), indicative of only “fair” to at best “substantial” agreement (Table 2).  
Following submission of the five sets of 50 genes selected by the different 
statistical methods to all three pathway databases as described in the methods section, 
some genes were found to be involved in more than one pathway described in one or 
more of the three databases, and in each set of selected genes, pathways were identified 
that involved more than one of these genes (Table 3). A total of 38 genes (Appendix B: 
Additional Table 1) could not be allocated to any pathway described in any of the three 
databases. We used Cohen’s kappa score to calculate agreement at the level of pathway 
identification between the five statistical methods. The κ –scores ranged from 0.30 to 
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0.79 as displayed in Table 3, which indicates mostly “moderate”, in three cases 
“substantial”, and twice only “fair” agreement between the five test methods. Most of the 
higher agreement scores were seen between Golub’s method and any one of the other 
methods.  
In order to assess the consistency between gene and pathway based inter-test 
similarities, the matrices reported in Table 2 and Table 3 were correlated to each other by 
means of Pearson’s correlation coefficient calculated between corresponding elements. 
The correlation coefficient of r = 0.916 points to a substantial equivalence between gene 
and pathway information and rules out possible bias due to differences in gene 
assignment to different pathways as a function of  the databases used.  
When the inter-test concordance matrix based on the diagnosis reported by Golub 
et al was correlated with the corresponding gene and pathway based matrices, we saw a 
complete lack of concordance between biological (gene and pathway) and clinical 
(diagnosis) levels (r = 0.055 and r=0.916 for gene-diagnosis and pathway-diagnosis 
consistency). 
Table 4 reports the inter-test pairwise k-scores for these three levels of analysis 
while Figure 1 shows the mutual correlation between gene-pathway and gene-patient 
inter-test correlation matrices. 
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Discussion 
 
DNA microarrays have much evolved over the past decade to become a dominant 
technology in the life sciences. The huge promise of this technology lies in its capacity to 
carry out high throughput analysis. As such, it is of great interest for both research in 
basic (patho-) physiology, as well as for screening assays towards “biomarkers” in an 
industrial setting. Microarrays produce vast amounts of data; analysis of this data 
provides information that ultimately serves to increase knowledge.  
Data, information and knowledge are closely related, but separate entities. They 
may be defined as simple observation (“data”, e.g. differential expression of signals on a 
microarray), data with relevance and purpose (“information” e.g. an expression signature 
used to classify samples) and valuable information from the human mind (“knowledge” 
e.g. different prognosis for AML and ALL cases classified by microarray through 
differential expression signals).4  
In a situation where data is commonly analyzed by variant approaches, it becomes 
imperious to ascertain the robustness of information gain and knowledge creation. In 
clinical settings, the robustness of information is commonly assessed by Cohen’s κ-score. 
This κ-score tests whether the inter-tester agreement is factual, or a product of chance. 
We used this simple and elegant method to assess to what extent the information gain 
from microarray data used for pathway discovery is more than a chance product.  
The overall κ-score of -28.01 is indicative of below chance agreement only: the 
agreement between the selected signatures is arbitrary, despite the formal similarities 
between the tests. This indicates that a per-chance choice of method is more likely to 
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succeed. Golub’s method is on average the ‘most correlated’ with the other tests, giving it 
a ‘central’ position. Both at the stage of gene selection, and of pathway identification, the 
inter-test agreement between the five statistical tests is, on average, only “fair” for 
selection and “moderate” for identification. Moreover, the gene and pathway based 
mutual similarities between tests are highly correlated, thus showing that the same basic 
information is carried by gene and pathway based analyses. 
The low kappa scores at the selection stage can be explained by the large 
“marginal imbalance” between selected genes (n=50) and unselected genes (n=6095)5,6. 
This, however, is not the case at the stage of pathway identification which in turn was 
completely consistent with the gene selection procedure with regards to the inter-test 
mutual relations.  Genes selected by different statistical methods may differ in name, but 
be involved in the same physiological functional systems of pathways because of 
redundancy of genes on the chip. This ‘regularization’ effect,  suggested by the 
enhancement of average k-scores going from gene to pathway level (from 0.344 to 
0.515),  is in any case marginal and does not substantially alter the inter-test agreement 
structure (r = 0.916 between gene and pathway based k-scores).  
The kappa scores for the pathway involvement show that the same data set, 
depending on which statistical method the researcher chooses to make use of, may 
provide considerably different “knowledge” gain. In other words, depending on which 
test is used on the same data set, different pathways are considered to be involved in the 
condition. Essentially the same conclusion, expressed in opposite terms, was drawn by 
Suarez- Farinas et al7, who showed that a normalized assessment of raw data from the 
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same tissue analyzed on different microarray platforms increased the consistency of 
results.  
Even more puzzling are the different findings obtained at the level of ‘case 
sample clustering’, i.e. the clinical (as opposed to the biological) level of appreciation of 
microarray data. In this case the inter-test concordance is much higher (average k-score 
0.75, range between 0.60 to 0.89), pointing to a much more robust information content. 
The inter-test similarity structure arising from the case sample classification is 
completely independent from the gene and pathway based similarity structures (Figure 1 
and Table 2). This points to a relative independence of the clinical judgement from the 
related biological explanation. In other words, it seems as if patients ‘respond’ with 
different expression signatures to the same disease condition, nevertheless maintaining an 
‘invariant gene expression signature’ at the level of the whole expression pattern that 
cannot be further decomposed to the level of single genes. 
In a recent study, Michiels et al. investigated the extent by which the composition 
of the “training set” (i.e. what samples are chosen to train the classifying algorithm) 
influences the final classification of “case samples”8. Depending on which “training 
samples” were chosen, the level of misclassification varied considerably. The larger the 
training set, the more robust the diagnosis became. In other words, an algorithm learns to 
correctly identify subclasses in the same way a physician does during his training: 
through studying as many training samples as possible. This opinion directly challenges 
the “robustness” of findings thought to be the main advantage of simply using gene 
clusters (“signatures”) from microarray expression profiles as “biomarkers” in study 
designs with few samples, but high dimensionality of signals9.  
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Do the observations demonstrated here disqualify microarray analysis as a valid 
technology to study biological phenomena? In our opinion, not at all. Technical problems 
concerning the reproducibility of findings even on the same platform have sparked 
research that resulted in more reliable data acquisition and analysis methods. By today, 
much information is gained from studies that use across- platform approaches and have 
advanced from the lab bench close to the bedside10,11. In particular, Suarez- Farina 
provided evidence that a normalized approach to data analysis will result in higher 
coherence of results7, while Michiels has drawn attention to the need to critically appraise 
this information before eventually accepting the newly gained knowledge8. Miller et al., 
whose objective was to test the diagnostic value of an expression signature, moreover 
recognized from thorough analysis of their data the primary importance of the p53 
functional status in predicting clinical breast cancer behavior12- that is, the quantitative or 
systemic behavior of the pathway rather than the common biomarker p53 predicts clinical 
outcome. In the setting of Miller et al’s study, the biomarker p53 is inferior with regards 
to prognostic accuracy compared to the DNA microarray expression “signature” 
described. If considered as a diagnostic tool, DNA microarrays achieve high agreement 
scores on par with experienced clinicians13. The problem of the large difference in 
dimensionality between the number of signals and the number of samples, as is common 
in microarray data, necessitate the scientist to decide on a trade-off against other 
techniques (e.g. PCR) where there is less dimensionality difference. This problem is a 
current focus of research interest; one possible solution may be a reversal of the matrix, 
that is, to classify large numbers of expression signals based on small numbers of clinical 
samples. In this case, from a purely statistical point of view, the problem loses it 
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degeneracy, because the genes (now considered as statistical units) become much more 
numerous than the biological samples (now considered as variables). This last research 
avenue was opened (among others) by Landgrebe et al.14 and by Tritchler et al.15 who 
applied the method to Golub’s data, too. This new perspective is extremely interesting as 
it implies a complete change of emphasis from considering single genes as ‘efficient 
causes’ of the disease towards understanding co-regulation networks of genes as 
‘measurable effects’ of the disease. 
Taken together, the analysis presented here shows that even after the critical 
analytic step of signal processing and normalizing, variation in analytical procedures may 
reduce the coherence of the conclusion.  
The observations reported in the present study should serve two immediate 
purposes. Firstly, the findings remind both technology developers and users that only 
validated information becomes knowledge. In view of the low agreement scores for 
pathway discovery shown here, information from microarray analysis must be considered 
very critically and not be accepted as knowledge too easily.  
Secondly, and in analogy to the technological refinements that have been put into 
place, our observations should encourage research into the refinement of statistical 
analysis methods.  
On a more general level, our results substantiate the need to progressively 
abandon the ‘single gene’ or even ‘pathway’ level of analysis in order to look at a 
different level of physiological co-regulation modes.  
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Methods 
 
We assessed the inter- test agreement as described by Cohen’s κ-score between 
five statistical tests 16-20 used in the analysis of DNA microarray expression data2. The 
data set analyzed was from the well characterized study on acute leukemia by Golub et al. 
which has a detailed methodology section that allows stepwise replication of the 
analysis16. The authors have updated their methodology and allow download from a 
dedicated website21. Appendix Part A gives a brief explanation of the five tests used, of 
Cohen’s kappa score, and of the original dataset. At the level of gene selection, Golub et 
al. employ an algorithm that requires specification of the number of genes one hopes to 
select from the “training” set of samples. Accordingly, we used alternative statistical 
approaches17-20 with the same formal requirement for comparison. The software 
GenePattern21 was used for data preprocessing. The preprocessed data was imported into 
the program R (The R Foundation for Statistical Computing, Version 2.1.1), in which all 
downstream analysis was performed (see Appendix Part B for the program codes). We 
submitted the gene sets (“signatures”) selected by each of the five classification methods 
to three databases that provide pathway information: BioCarta22, KEGG PATHWAY23, 
and Reactome24 (Appendix C). The gene sets selected from the training samples used by 
Golub and the pathways identified were then compared by calculating the kappa scores. 
κ-scores are reported at the level of gene-selection and pathway identification on the 
“training” samples.  
The matrices reporting the pairwise inter-tests κ-scores relative to the 
concordance were correlated at the level of gene-selection and pathway identification so 
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as to assess the consistency of the observed inter-test similarities at the gene and pathway 
levels. Both these matrices were then compared with the “case sample clustering” matrix 
reporting the inter-tests  κ-scores agreement with clinical diagnosis. 
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Tables 
 t-test Golub SAM EBAM nMigs 
t-test 50 38 26 31 8 
Golub  50 38 25 5 
SAM   50 18 3 
EBAM    50 11 
nMigs     50 
Table 1: Overview of number of genes selected by each pair of the five statistical 
methods  
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 Gene Pathway Patient 
Gene 1.00 0.92 
(0.0002) 
0.06 
(0.8788) 
Pathway  1.00 
 
0.18 
(0.6275) 
Patient   1.00 
 
Table 2: Kappa scores for agreement of “gene selection from training set” between the 
five methods (average = 0.34; “fair”) 
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 t-test Golub SAM EBAM nMigs 
t-test 1.00 0.61 0.30 0.79 0.55 
Golub  1.00 0.60 0.51 0.53 
SAM   1.00 0.34 0.44 
EBAM    1.00 0.48 
nMigs     1.00 
Table 3: Kappa scores for agreement of “pathway involved” between the five methods 
(average = 0.52; “moderate”) 
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Pairname Gene Pathway Patient 
t-Golub 0.52 0.61 0.85 
t-SAM 0.15 0.3 0.6 
t-EBAM 0.68 0.79 0.75 
t-nMigs 0.25 0.55 0.75 
Golub-SAM 0.54 0.6 0.65 
Golub-EBAM 0.4 0.51 0.79 
Golub-nMigs 0.31 0.53 0.68 
SAM-EBAM 0.15 0.34 0.78 
SAM-nMigs 0.19 0.44 0.78 
EBAM-nMigs 0.25 0.48 0.89 
Table 4: Inter-test pairwise k-scores at the levels of gene,  
pathway and patient identification  
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Figures  
Figure 1: Mutual correlation between (a) gene-pathway and (b) gene-patient inter-test 
correlation matrices. 
 
